BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36504622)

  • 21. The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
    Pawlikowska L; Nelson J; Guo DE; McCulloch CE; Lawton MT; Young WL; Kim H; Faughnan ME;
    Am J Med Genet A; 2015 Jun; 167(6):1262-7. PubMed ID: 25847705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
    Latif MA; Sobreira NLD; Guthrie KS; Motaghi M; Robinson GM; Shafaat O; Gong AJ; Weiss CR
    Am J Med Genet A; 2021 Jul; 185(7):1981-1990. PubMed ID: 33768677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.
    Han C; Choe SW; Kim YH; Acharya AP; Keselowsky BG; Sorg BS; Lee YJ; Oh SP
    Angiogenesis; 2014 Oct; 17(4):823-830. PubMed ID: 24957885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of arteriovenous malformations in the absence of endoglin.
    Mahmoud M; Allinson KR; Zhai Z; Oakenfull R; Ghandi P; Adams RH; Fruttiger M; Arthur HM
    Circ Res; 2010 Apr; 106(8):1425-33. PubMed ID: 20224041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
    Lee ST; Kim JA; Jang SY; Kim DK; Do YS; Suh GY; Kim JW; Ki CS
    J Korean Med Sci; 2009 Feb; 24(1):69-76. PubMed ID: 19270816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis.
    Brinjikji W; Iyer VN; Wood CP; Lanzino G
    J Neurosurg; 2017 Aug; 127(2):302-310. PubMed ID: 27767404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia.
    Choi EJ; Chen W; Jun K; Arthur HM; Young WL; Su H
    PLoS One; 2014; 9(2):e88511. PubMed ID: 24520391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations.
    Nishida T; Faughnan ME; Krings T; Chakinala M; Gossage JR; Young WL; Kim H; Pourmohamad T; Henderson KJ; Schrum SD; James M; Quinnine N; Bharatha A; Terbrugge KG; White RI
    Am J Med Genet A; 2012 Nov; 158A(11):2829-34. PubMed ID: 22991266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical presentation and treatment paradigms of brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.
    Gamboa NT; Joyce EJ; Eli I; Park MS; Taussky P; Schmidt RH; McDonald J; Whitehead KJ; Kalani MYS
    J Clin Neurosci; 2018 May; 51():22-28. PubMed ID: 29483005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
    Tillet E; Bailly S
    Front Genet; 2014; 5():456. PubMed ID: 25620979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMAD4 maintains the fluid shear stress set point to protect against arterial-venous malformations.
    Banerjee K; Lin Y; Gahn J; Cordero J; Gupta P; Mohamed I; Graupera M; Dobreva G; Schwartz MA; Ola R
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37490341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.
    Genet G; Genet N; Paila U; Cain SR; Cwiek A; Chavkin NW; Serbulea V; Figueras A; Cerdà P; McDonnell SP; Sankaranarayanan D; Huba M; Nelson EA; Riera-Mestre A; Hirschi KK
    Circulation; 2024 Mar; 149(12):944-962. PubMed ID: 38126211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.
    Ardelean DS; Letarte M
    Front Genet; 2015; 6():35. PubMed ID: 25717337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype-Phenotype Correlations in Children with HHT.
    Kilian A; Latino GA; White AJ; Clark D; Chakinala MM; Ratjen F; McDonald J; Whitehead K; Gossage JR; Lin D; Henderson K; Pollak J; McWilliams JP; Kim H; Lawton MT; Faughnan ME;
    J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32842615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia.
    Dinakaran S; Zhao H; Tang Y; Wang Z; Ruiz S; Nomura-Kitabayashi A; Blanc L; Faughnan ME; Marambaud P
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1.
    Albiñana V; Zafra MP; Colau J; Zarrabeitia R; Recio-Poveda L; Olavarrieta L; Pérez-Pérez J; Botella LM
    BMC Med Genet; 2017 Feb; 18(1):20. PubMed ID: 28231770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2.
    Choi EJ; Kim YH; Choe SW; Tak YG; Garrido-Martin EM; Chang M; Lee YJ; Oh SP
    PLoS One; 2013; 8(5):e63138. PubMed ID: 23675457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective Flow-Migration Coupling Causes Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.
    Park H; Furtado J; Poulet M; Chung M; Yun S; Lee S; Sessa WC; Franco CA; Schwartz MA; Eichmann A
    Circulation; 2021 Sep; 144(10):805-822. PubMed ID: 34182767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.
    Ruiz S; Zhao H; Chandakkar P; Papoin J; Choi H; Nomura-Kitabayashi A; Patel R; Gillen M; Diao L; Chatterjee PK; He M; Al-Abed Y; Wang P; Metz CN; Oh SP; Blanc L; Campagne F; Marambaud P
    J Clin Invest; 2020 Feb; 130(2):942-957. PubMed ID: 31689244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.